The chief executive officer of OxyContin-maker Purdue Pharma LP should not collect a potential $1.3 million bonus when he has been accused of contributing to the opioid epidemic, a group of state attorneys general said in a court filing.
Purdue Pharma LP will ask a U.S. Bankruptcy Judge to pause litigation against the company and ownership over the objections of U.S. states that allege the OxyContin maker is trying to protect the controlling Sackler family.
Less than one month after filing for bankruptcy, uBiome is shutting the Bay Area microbiome company’s doors and selling off assets.
Southern California-based Sienna Biopharmaceuticals filed for bankruptcy, which sent share prices tumbling more than 73 percent.
Purdue Pharma filed for Chapter 11 bankruptcy and agreed to pay between $10 and $12 billion to settle the drug manufacturer’s involvement in the health-care crisis.
OxyContin maker Purdue Pharma LP reached a tentative agreement with some plaintiffs to resolve litigation over the company’s alleged role in fueling the U.S. opioid crisis and plans to tussle with states opposing the settlement offer in bankruptcy proceedings, people familiar with the matter said.
Days after agreeing to pay nearly $225 million in additional fines to the U.S. government for fraudulent marketing schemes to boost sales of the opioid Subsys, Insys Therapeutics filed for bankruptcy.
Enumeral Biomedical filed for bankruptcy protection and is selling its assets to Xoma Corporation for $1.6 million.
A lawsuit brought against beleaguered blood-testing company Theranos alleges the company committed fraud by faking its blood-testing demonstrations.